Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease

Behavioural Brain Research

Volumn 113, Issue 1-2, 2000, Pages 199-206

  Maelicke, Alfred ^a,b   Schrattenholz, Andre ^a   Samochocki, Marek ^a   Radina, Martin ^a   Albuquerque, Edson X ^b  

^a Laboratory of Molecular Neurobiology   (Germany)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Allosterically potentiating ligand; Alzheimer; Cholinergic deficit; Galanthamine; Nicotinic acetylcholine receptor; Patch clamp; Physostigmine

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ALKALOID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CODEINE; GALANTAMINE; GLYCINE; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC AGENT; NICOTINIC RECEPTOR; PHYSOSTIGMINE; RECEPTOR SUBTYPE; SEROTONIN;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ARTICLE; DRUG MECHANISM; DRUG TARGETING; HUMAN; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ALZHEIMER DISEASE; ANIMALS; CELL LINE; HUMANS; MICE; NEURONS; NICOTINIC AGONISTS; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION;

EID: 0033845742     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00214-X     Document Type: Article

References (64)

1. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotinie-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
2. Albuquerque E.X., Alkondon M., Pereira E.F., Castro N., Schrattenholz A., Barbosa C., Bonfante-Cabarcas R., Aracava Y., Eisenberg H., Maelicke A. Properties of neuronal nicotinic acetylcholine receptors, pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280:1996;1117-1136.
3. Albuquerque E.X., Pereira E.F.R., Bonfante-Cabarcas R., Marchioro M., Matsubayashi H., Alkondon M., Maelicke A. Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity. Prog. Brain Res. 109:1996;111-124.
4. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors. Eur. J. Neurosci. 9:1997;2734-2742.
5. Alkondon M, Pereira EFR, Eisenberg H, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci (1999), in press.
6. Alkondon M., Pereira E.F.R., Eisenberg H.M., Albuquerque E.X. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J. Neurosci. 19:1999;2693-2705.
7. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
8. Bertrand D., Changeux J.P. Nicotinic receptor: an allosteric protein specialized for intercellular communication. Semin. Neurosci. 7:1995;75-90.
9. Bjugstad K., Mahnir V., Klein W., Socci D., Arendash G. Long term treatment with GTS-21 or nicotine enhances water maze performance in aged rates without affecting the density of nicotinic receptor subtypes in neocortex. Drug Dev. Res. 39:1996;19-28.
10. Buisson B., Bertrand D. Allosteric modulation of neuronal nicotinic acetylcholine receptors. J. Physiol. 92:1998;89-100.
11. Castro N.G., Albuquerque E.X. Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys. J. 68:1995;516-524.
12. Court J.A., Perry E.K. CNS nicotine receptors. Possible therapeutic targets in neurodegenerative disorders. CNS Drugs. 2:1994;216-233.
13. Davis K.L., Yamamura H.L. Cholinergic undeeractivity in human memory disorders. Life Sci. 23:1978;1729-1734.
14. Descarries L. The hypothesis of an ambient level of acetylcholine in the central nervous system. J. Physiol. 92:1998;215-220.
15. Feldman H., Gracon S. Alzheimer's disease: symptomatic drugs under development. Gauthier S. Clinical Diagnosis and Management of Alzheimer's Disease. 1996;Martin Dunitz, London.
16. Flicker L. Acetylcholinesterase inhibitors for Alzheimer's disease. Br. Med. J. 318:1999;615-616.
17. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 66:1999;137-147.
18. Freedman R., Coon H., Mylesworsley M., Orr-Utreger A., Olincy A., Davis A. Linkage of neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:1997;587-592.
19. 3H) chlorpromazine labels homologous residues in the beta and delta chains. Biochemistry. 26:1987;2410-2418.
20. Hsu Y., Amin J., Weiss D., Wecker L. Sustained nicotine exposure differentially affects α3β2 and α4β2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66:1996;667-675.
21. Jürss R., Prinz H., Maelicke A. NBD-5-acylcholine: fluorescent analog of acetylcholine and agonist at the neuromuscular junction. Proc. Natl. Acad. Sci. USA. 76:1979;1064-1068.
22. Katz B., Miledi R. A reexamination of curare action at the motor endplate. Proc. R. Soc. Lond. B. 196:1977;59-72.
23. Kihara T., Shimohama S., Urushitani M., Sawanda H., Kimura J., Kume T., Maeda T., Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792:1998;331-334.
24. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22:1996;431-445.
25. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl). 138:1998;217-230.
26. Levey A.I. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 93:1996;13541-13546.
27. Maelicke A. Biochemical aspects of cholinergic excitation. Angew. Chem. Int. Ed. 23:1984;195-221.
28. Maelicke A., Albuquerque E.X. New approach to drug therapy of Alzheimer's dementia. Drug Discov. Today. 1:1996;53-59.
29. Maelicke A., Schrattenholz A., Schröder H. Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system. Semin. Neurosci. 7:1995;103-114.
30. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., Tzartos S., Ballard C., Perry R.H., Perry E.K. α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem. 73:1999;1635-1640.
31. McDonald R.L., Twyman R.E. Kinetic properties and regulation of GABA receptor channels. Ion Channels. 3:1992;315-343.
32. Menzaghi F., Whelan K., Risbrough V., Rao T., Lloyd G. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J. Pharmacol. Exp. Ther. 280:1997;384-392.
33. Newhouse P.A., Sunderland T., Tariot P.N., Blumhardt C.L., Weingartner H., Mellow A. et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology. 95:1988;171-175.
34. Newhouse P.A., Potter A., Corwin J., Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 10:1994;93-107.
35. Nordberg A., Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 19:1998;465-480.
36. 3H) acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-119.
37. Nordberg A., Lundqvist A., Hartvig P. et al. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains: in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
38. Peng X., Gerzanich V., Anand R., Wang F., Lindstrom J. Chronic nicotine treatment upregulates α3 AChRs and α7 AChRs expressed by the human neuroblastoma cell line SH-SY5Y. Mol. Pharmacol. 51:1997;776-784.
39. Pereira E.F.R., Alkondon M., Tano T., Castro N.G., Froes-Ferrao M.M., Rosental R., Aronstam R.S., Albuquerque E.X. A novel agonist binding site on nicotinic acetylcholine receptors. J. Recept. Res. 13:1993;413-436.
40. Pereira E.F.R., Reinhardt-Maelicke S., Schrattenholz A., Maelicke A., Albuquerque E.X. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 265:1993;1474-1491.
41. Pereira E.F.R., Alkondon M., Reinhardt S., Maelicke A., Peng X., Lindstrom J., Whiting P., Albuquerque E.X. Physostigmine and galanthamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther. 270:1994;768-778.
42. Perry E., Morris C., Court J., Cheng A., Fairbairn A., McKeith I., Irving D., Brown A., Perry R. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology. Neuroscience. 64:1995;385-395.
43. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289:1999;1545-1552.
44. Potter A., Corwin J., Lang J., Piasecki M., Lenox R., Newhouse P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology. 142:1999;334-342.
45. Raiteri M., Marchi M., Paudice P. Presynaptic muscarinic receptors in the central nervous system. Ann. N. Y. Acad. Sci. 604:1990;113-129.
46. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
47. Russo C., Marchi M., Andrioli G.C., Cavazzani P., Raiteri M. Enhancement of glycine release from human brain cortex synaptosomes by acetylcholine acting at M4 muscarinic receptors. J. Pharmacol. Exp. Ther. 266:1993;142-146.
48. Sabey K., Paradiso K., Zhang J., Steinbach J.H. Ligand binding and activation of rat nicotinic α4β2 receptors stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 55:1999;58-66.
49. Schrattenholz A., Godovac-Zimmermann J., Schäfer H.J., Albuquerque E.X., Maelicke A. Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur. J. Biochem. 216:1993;671-677.
50. Schrattenholz A., Pereira E.F.R., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49:1996;1-6.
51. Schrattenholz A., Roth U., Godovac-Zimmermann J., Maelicke A. Mapping of a binding site for ATP within the extracellular region of the Torpedo nicotinic acetylcholine receptor β-subunit. Biochemistry. 36:1997;13333-13340.
52. Schröder H., Giacobini E., Strubble R.G., Zilles K., Maelicke A. Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging. 12:1991;259-262.
53. Schröder B., Reinhardt S., Schrattenholz A., McLane K.E., Kretschmer A., Conti-Tronconi B.M., Maelicke A. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor α-polypeptide. J. Biol. Chem. 269:1994;10407-10416.
54. Shaw K.P., Aracava Y., Akaike A., Daly J.W., Rickett D.L., Albuquerque E.X. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol. 28:1985;527-538.
55. Storch A., Schrattenholz A., Cooper J.C., Abdel Ghani M., Gutbrod O., Weber K.-H., Reinhardt S., Lobron C., Hermsen B., Soskic V., Pereira E.F.R., Albuquerque E.X., Methfessel C., Maelicke A. Physostigmine, galanthamine and codeine act as non-competitive nicotinic agonists on clonal rat pheochromocytoma cells. Eur. J. Pharmacol. 290:1995;207-219.
56. Thal L.J., Ferguson J.M., Mintzer J., Rskin A., Targum S.D. A 24-week randomized trial of controlled-release phsyostigmine in patients with Alzheimer's disease. Neurology. 52(6):1999;1146-1152.
57. Valera S., Ballivet M., Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA. 89:1992;9949-9953.
58. Vernino S., Amador M., Luetje C.W., Patrick J., Dani J.A. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron. 8:1992;127-134.
59. Warpman U., Nordberg A. Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains. Neuroreport. 6:1995;219-2423.
60. Wevers A., Monteggia L., Lowack S., Bloch W., Schütz U., Lindstrom J., Pereira E.F.R., Arneric S., Sullivan J., Eisenberg H., Giacobini E., Gass P., deVos R.A.I., Jansen S.E.N.H., Maelicke A., Albuquerque E.X., Schröder H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease - histotopographical correlation with amyloid plaques and hyperphosphorylated tau-protein. Eur. J. Neurosci. 11:1999;2551-2555.
61. Whitehouse P.J., Martino A.M., Antuono P.G. et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1:1986;55-65.
62. Wilson A.L., Langley L.K., Monley J., Bauer T., Rottunda S., McFalls E., Kovera C., McCarten J.R. Nicotine patches in Alzheimer's disease: pilot study on learning, memory and safety. Pharmacol. Biochem. Behav. 51:1995;509-514.
63. Wonnacott S., Marks M.J. Nicotine: not just for cigaretts anymore. Drug Discov. Today. 4(11):1999;490-492.
64. Zwart R., Vijverberg H.P.M. Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol. Pharmacol. 52:1997;886-895.